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Enterococci possess capsular carbohydrate antigens that are targets of opsonic antibodies. These antigens
may be used to develop alternative options for the treatment and prevention of enterococcal infections. The
present study was done to analyze the diversity of capsular polysaccharides in Enterococcus faecalis. Four
type-specific sera were used in an enzyme-linked immunosorbent assay format to detect polysaccharide antigen
extracted from bacterial cell walls. A total of 55% of a collection of 29 E. faecalis strains could be grouped into
one of four serogroups. Additional analysis of the strains by opsonophagocytic assays revealed agreement
between the results of the two methods for 72% of the isolates. An additional four strains could be assigned to
a serogroup on the basis of opsonic killing by sera with antibodies against the four prototypes strains,
provisionally named CPS-A to CPS-D. The results of the two methods disagreed for one strain (4%). When the
results of both methods were combined, 66% of the strains could be classified. One strain had to be assigned
to two serogroups. The assignments to the four serogroups were confirmed by analysis of the genetic organi-
zation of the biosynthetic capsular polysaccharide (cps) locus. All strains grouped into serotypes CPS-A and
CPS-B possessed only the cpsA and cpsB genes, while all strains grouped into serogroups CPS-C and CPS-D
possessed an additional eight or nine genes. Our results suggest the existence of a limited number of E. faecalis
capsule serotypes, and we provisionally propose four serotypes, named CPS-A to CPS-D, and the respective
prototype strains for these families.
Enterococci are one of the leading causes of infections in
hospitalized patients and the third most common cause of
nosocomial bloodstream infections in the United States (6–8,
20). The number of strains resistant to virtually all clinically
available antibiotics is increasing (20). Recent studies demon-
strate that up to 25% of enterococcal hospital isolates are
resistant to glycopeptide antibiotics (1, 20), the mainstay of the
therapeutic armory. Resistant enterococcal strains cause sig-
nificant morbidity and mortality, especially among immuno-
compromised patients.
Huebner et al. (16) recently identified a capsular polysac-
charide in an Enterococcus faecalis strain and a vancomycin-
resistant E. faecium strain that is the target of opsonic anti-
bodies. Compositional and structural analyses revealed a
teichoic acid-like molecule. Antibodies raised against this an-
tigen protected mice in an experimental model of systemic
enterococcal infection (15), thus offering new options for treat-
ment and prevention. In 2002, Hancock and colleagues (10, 12)
identified a genetic locus involved in the biosynthesis of a cell
wall polysaccharide of E. faecalis strain FA2-2. This strain
reacts with a type-specific antiserum raised against Maekawa
E. faecalis strain type 2 (19). The corresponding cps locus
consists of 11 open reading frames.
Some clues to the diversity of E. faecalis capsular polysac-
charides can be gleaned from previous attempts to establish
serotyping systems (19, 24), although it is not known at present
how many structurally different capsular polysaccharides exist.
Sharpe and Shattok (24) used HCl extracts of bacteria to raise
rabbit sera with antibodies against surface polysaccharides.
Their serotyping scheme is likely based on polysaccharide an-
tigens, but considerable taxonomic changes subsequent to de-
velopment of the scheme (19) limited its applicability. Mae-
kawa et al. (19) used formaldehyde-killed bacteria to immunize
rabbits against 21 prototype strains. Their serogroups are prob-
ably based not only on polysaccharide antigens but on a num-
ber of different surface antigens as well.
With an interest in the ultimate development of immuno-
therapeutics, we undertook a study to reexamine the diversity
of E. faecalis capsules using strains identified by modern tax-
onomy and to compare the serological diversity observed with
the organization of the genes in the recently identified E. fae-
calis capsule locus (10).
(This work was presented in part at the 101st General Meet-
ing of the American Society for Microbiology, Orlando, Fla.,
2001.)
MATERIALS AND METHODS
Strains, culture, and sera. The bacterial strains and sera used in these studies
are described in Tables 1 and 2 (10, 15–17, 19, 21). E. faecalis 12030 is the only
E. faecalis strain for which structural information on the capsular polysaccharide
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exists (16, 27). Strain E. faecalis 12107 (15) is a clinical isolate from the United
States, and the 21 prototype E. faecalis strains previously described by Maekawa
et al. (19) are of E. faecalis types 2 and 5. HG101 is an insertion mutant of
laboratory strain FA2-2 that is unable to produce the capsular polysaccharide
(10). All E. faecalis strains were grown without agitation at 37°C either in
Todd-Hewitt broth (Becton Dickinson, Sparks, Md.) or, for the capsular polysac-
charide-specific enzyme-linked immunosorbent assay (CPS-ELISA), in Colum-
bia broth (Difco Laboratories, Detroit, Mich.) with the addition of 0.5% glucose.
Erythromycin (Sigma Chemical Co., St. Louis, Mo.) was added at a concentra-
tion of 10 g/ml for mutant strain HG101.
Sera with antibodies against the purified capsular polysaccharides of strains
E. faecalis 12030 (15) and E. faecalis 12107 (16) were prepared as described
elsewhere (15). In addition, sera with antibodies against two of the prototype
strains described by Maekawa et al. (19) (E. faecalis Maekawa type 2 and E.
faecalis Maekawa type 5) were prepared by using heat-killed and proteinase
K-treated whole bacterial cells. New Zealand White rabbits were injected with
two doses of 100 g of purified polysaccharide antigen subcutaneously and three
doses of 10 g of purified polysaccharide antigen intravenously as described
previously (15). Immunization with whole bacterial cells (i.e., E. faecalis type 2
and type 5) was done by using doses of 3  108 bacteria injected intravenously
three times a week for 5 weeks. The bacterial cells were heat killed (70°C for 1 h)
and digested with proteinase K (0.1 mg/ml at 56°C for 1 h; Invitrogen, Carlsbad,
Calif.) prior to intravenous injection. Rabbits were bled 5 weeks after the last
injection and periodically for 20 weeks without boosting. The resulting four
groups of serum samples, representing four serologically distinct families, were
used in a newly developed capsular polysaccharide-specific ELISA (CPS-ELISA)
and in opsonophagocytic assays.
CPS-ELISA. Crude polysaccharide extracts were prepared from the entero-
coccal strains. Bacteria were grown overnight at 37°C to stationary phase in 50 ml
of Columbia broth supplemented with 0.5% glucose. The cell pellet was sus-
pended in 500 l of 10% trichloroacetic acid (TCA) and incubated on a rotor
rack at 4°C for 18 to 24 h (a modification of the procedure of Heckels and Virji
[13]). The suspension was then centrifuged at 12,000 rpm for 10 min (Hettich
Micro 20 instrument), and the supernatant was precipitated with 1.25 ml of
ethanol overnight at 20°C. After centrifugation (10 min at 12,000 rpm) the
supernatant was discarded and the pellet was dissolved in 1 ml of distilled H2O.
Microtiter plates (96 wells; Immulon 2HB; Dynex Technologies, Chantilly, Va.)
were coated overnight with 80 l of antigen solution along with 20 l of 5
sensitizing buffer (180 mg of NaH2PO4 and 1.7 g of NaHPO4 per 100 ml) at 4°C.
The plates were washed three times with phosphate-buffered saline (PBS),
blocked with 3% skim milk in PBS for 1 h, and again washed three times with
PBS. The primary antibody was applied in dilutions of 1:100 and 1:500, and the
plates were incubated for 60 min at 37°C. In order to eliminate cross-reactivity
and to improve specificity, all four prototype groups of sera were absorbed with
either one or a combination of three different heterologous E. faecalis strains
(Table 2). All serum samples were absorbed at a 1:20 dilution with 2  109
bacteria per ml at 4°C for 60 min on a rotor rack. This procedure was done three
times for every serum sample. After an additional washing step, the secondary
antibody (goat anti-rabbit alkaline phosphatase-conjugated immunoglobulin G
antibody; ICN Biomedicals, Aurora, Ohio) was applied at a dilution of 1:1,000
and the mixture was incubated for 60 min at 37°C. After the plates were washed
with PBS, the detection reagent p-nitrophenyl-phosphate (Sigma Chemical Co.)
was added. The plates were read at 405 nm after 15, 30, 60, and 90 min in an EL
309 ELISA reader (Bio-Tek Instruments, Winooski, Vt.). Each strain was tested
at least in duplicate. Both positive and negative controls were included on all
plates.
Characterization of TCA extracts. For quantitative measurement of the pro-
tein contents of TCA extracts, a modified dye-binding assay of Bradford (9) was
used. For quantitative estimation of the carbohydrate contents of TCA extracts,
the phenol-sulfuric acid method was performed (9).
Opsonophagocytic assays. Opsonophagocytic assays with all enterococcal
strains were performed as described elsewhere (16). Each bacterial strain was
tested with the four groups of unabsorbed prototype sera. In addition, the sera
were absorbed either with the homologous, immunizing strain or with single or
multiple combinations of heterologous prototype strains (Table 2). Samples
without serum and samples with normal rabbit serum (NRS) were used as
controls, and each experiment was performed at least in duplicate. The percent
killing was calculated by comparing the inoculum (viable counts at time zero
[T0]) with the colony counts obtained after incubation for 90 min at 37°C (T90)
on a rotor rack by use of the following formula: [(mean CFU at T0  mean CFU
at T90)/(mean CFU at T0)]  100.
Immunoelectron microscopy. Immunoelectron microscopy was performed
with the four prototype strains, E. faecalis 12030, 12107, type 2, and type 5, as
described elsewhere (16). The four groups of unabsorbed sera (data not shown)
and all four groups of sera absorbed either with the homologous strain or with
each of the three heterologous strains were used as primary antibodies.
PCR analysis of cps locus. The primers and PCR conditions used to amplify
the 11 genes of the cps locus have been described elsewhere (10).
Restriction fragment length polymorphism (RFLP) analysis of the cps locus.
Southern blot hybridization analysis of chromosomal DNA digested with differ-
ent restriction enzymes (Invitrogen) was performed as described elsewhere (10).
RESULTS
Generation of capsule-specific antisera. Four groups of rab-
bit sera with antibodies against enterococcal surface polysac-
charide antigens were prepared to establish a system for the
serotyping of E. faecalis. Each of the four groups of sera re-
acted specifically with the homologous strain (Fig. 1), outlining
a capsule-like structure in all cases. Absorption of the respec-
tive serum group with the corresponding homologous strain
abolished the visualization of the capsule-like structure (Fig. 1,
second column), whereas absorption of the four groups of sera
with any of the three heterologous strains had no effect on the
ability to visualize the capsule (Fig. 1, columns three to five).
This indicates that all four groups of sera reacted with antigens
present on the surface of the bacterial cells and that each type
of serum bound specifically to its prototype strain. Only low
levels of binding of gold-labeled protein A were observed when
NRS was used as a negative control (data not shown).
Type-specific reactivity of antisera. Three of the groups of
absorbed prototype sera (i.e., 12030, 12107, and Type 5;
Table 2) reacted only with the corresponding prototype strain
by CPS-ELISA (Table 3). The type 2-specific serum reacted
with both E. faecalis type 2 and E. faecalis type 5 antigens,
indicating cross-reactivity between the two strains (Table 3).
TABLE 1. E. faecalis strains used in the present study
Strain Origin (reference or source)
12030 .........................Clinical isolate (16)
12107 .........................Clinical isolate (15)
type 1–21...................Prototype Japanese strains from Maekawa et al. (19)
FA2-2.........................Laboratory strain
HG101.......................cpsI mutant of FA2-2 (10)
OG1-RF ....................Laboratory strain (ATCC 47077)
V583 ..........................Vancomycin-resistant clinical strain (ATCC 700802)
MMH 594 .................Epidemic strain (17)
R19.001 .....................Epidemic strain from Children’s Hospital, Boston,
Mass. (21)
68114 .........................Clinical isolate
TABLE 2. Sera and serum absorptions used in the present study
Antigen against which
immune rabbit serum
was directed
E. faecalis strain(s)
used for absorption
in CPS-ELISA
Homologous and
heterologous strains
used for absorption
in opsonophago-
cytic assay
Strain 12030 polysaccharide Type 20 12030,a 12107b
Strain 12107 polysaccharide 68114 12107,a 12030b
Type 2 whole bacteria (heat
and proteinase K treated)
12107 Type 2,a 12030b and
12107b
Type 5 whole bacteria (heat
and proteinase K treated)
12030, 12107, type 2 Type 5,a 12030b and
12107b
a Homologous strain.
b Heterologous strain.
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This cross-reactivity was further substantiated by the testing of
the two strains in an absorption CPS-ELISA (Fig. 2). The two
groups of sera were absorbed with the respective homologous
strains as well as with each of the three heterologous strains.
Binding of both groups of sera was reduced by absorption with
the homologous strain (84% reduction for the type 5-specific
serum, 91% reduction for the type 2-specific serum). Absorp-
tion of the two groups of sera with the respective heterologous
strain, E. faecalis type 2 or E. faecalis type 5, led to a higher
degree of reduction (57% reduction for the type 5-specific
serum, 83% reduction for the type 2-specific serum) than ab-
sorption with the heterologous strains, E. faecalis 12030 or
E. faecalis 12107 (levels of reduction, between 11 and 22%).
Despite the cross-reactivity of the type 2-specific serum be-
FIG. 1. Immunoelectron microscopy of the four prototype E. faecalis (EFS) strains labeled with the prototype serum absorbed with either the
homologous strain or the three heterologous strains.
2550 HUFNAGEL ET AL. J. CLIN. MICROBIOL.
tween E. faecalis type 2 and E. faecalis type 5, these two strains
were distinguished in the CPS-ELISA. Type 2-related strains
showed high levels of reactivity (as determined by measure-
ment of the optical density at 405 nm [OD405]) with the type
2-specific serum but low levels of reactivity with the type 5-spe-
cific serum. In contrast, type 5-related strains reacted with both
types of sera, with the strains having higher levels of reactivity
with type 5-specific serum than type 2-specific serum (134 and
100%, respectively; Table 3).
Diversity of binding of antisera to capsular polysaccharides
in the CPS-ELISA. The assignment of a test strain to a proto-
type strain was made if the OD405 was at least 70% of the value
obtained with the corresponding prototype strain (Table 3).
This threshold was chosen on the basis of the assumption that
the reactivity of a related strain with one of the prototype
groups of sera should exceed the cross-reactivity of the other
three heterologous prototype strains with the respective groups
of sera. The following formula was used to obtain a threshold
value: sum of the OD405s of all four groups of sera reacting
with all three heterologous strains divided by the sum of the
OD405s of all four groups of sera reacting with the respective
homologous strains. A value of 62.9% was obtained by this
FIG. 2. Absorption CPS-ELISA of E. faecalis (EFS) type 2 and type 5 prototype strains with the two corresponding prototype sera. The two
types of sera were absorbed either with the respective homologous strain or with each of the three heterologous strains. The percent absorption
values reflect the ratio of the amount of absorbed sera to the amount of unabsorbed sera. Both types of sera could be absorbed with the
homologous strain (84 and 91%, respectively). Absorption of both types of sera with heterologous strains E. faecalis type 2 and E. faecalis type 5,
respectively, led to a higher degree of absorption (57 and 83%, respectively) than absorption with the heterologous strains E. faecalis 12030 and
E. faecalis 12107 (range, 11 to 22%).
TABLE 3. Results of CPS-ELISA with TCA extracts
of 14 E. faecalis strains
Proposed
serogroup
E. faecalis
strain
OD405a
12030 12107 Type 2 Type 5
CPS-A 12030 2.56 0.772 0.456 0.324
Type 7 1.855 0.495 0.459 0.253
CPS-B 12107 0.232 2.529 0.501 0.356
Type 1 0.275 2.232 0.843 0.306
OG1-RF 0.319 2.263 0.489 0.285
CPS-C Type 2 0.586 0.384 2.444 0.243
FA2-2 0.469 0.546 1.86 0.818
Type 12 0.254 0.306 2.029 0.218
R19.001 0.288 0.642 2.402 0.33
V583 0.42 0.718 2.476 0.514
CPS-D Type 5 0.222 0.482 1.128 1.512
Type 18 0.523 0.482 0.976 1.305
CPS-C/D MMH 594 0.184 0.337 2.388 2.396
NTb Type 9 0.347 0.775 1.4 0.515
a The OD405s of the four prototype groups of sera for the respective prototype
strain are shown in boldface and italic. Boldface alone indicates the assignment
of the strain to one of the four prototype strain types.
b NT, nontypeable.
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formula. To decrease the error margin, a 70% cutoff was finally
chosen as the assignment criterion.
A panel of 29 different E. faecalis strains was tested by the
CPS-ELISA. By using the criteria described above, 55% (i.e.,
16 of 29) of the strains tested could be classified into one of the
four serotypes. One strain (E. faecalis MMH 594) reacted with
two groups of sera (i.e., type 2- and type 5-specific sera), and
thus, 41% (12 of 29) of the strains could not be classified
unambiguously by the CPS-ELISA.
Diversity of capsular polysaccharides in opsonophagocytic
killing. To confirm the findings obtained by CPS-ELISA, all
strains were analyzed by opsonophagocytic assays that tested
for a clinically relevant biological function, i.e., the opsonic
killing activity of the sera. To assess the specificity of the
killing, the sera were absorbed with the respective homolo-
gous strain as well as with different heterologous strains
(Table 2). Isolates were assigned to one of the four sero-
types if (i) opsonic killing by a prototype serum was greater
than 70% and (ii) the killing was abolished by more than
50% by absorption with the homologous strain but not to the
same degree by absorption with the heterologous strains.
Again, the three prototypes strains, E. faecalis 12030, E. fae-
calis 12107, and E. faecalis type 5, were most effectively killed
and, according to the assignment criterion, were also specifi-
cally killed by their homologous sera (Fig. 3). Type 2-specific
serum killed both E. faecalis type 2 and E. faecalis type 5,
supporting the findings of cross-reactivity between these two
strains. Ten of the 29 (34%) E. faecalis strains could be unam-
biguously assigned to one of the four serotypes. For a further
24% (7 of 29) of the strains, the opsonic killing activity was not
able to distinguish between type 2- or type 5-related strains.
One strain (Maekawa strain type 7) was killed to the same
degree by both strain 12030- and strain 12107-specific sera.
The overall agreement between the CPS-ELISA and the op-
sonophagocytic assay was 72% (21 of 29 strains). Seven (24%)
strains that were nontypeable by one assay could be assigned to
a serogroup by the other test. Only one strain (Maekawa strain
type 6 strain) gave conflicting results by the two assays.
When the results of the two assays are taken together, 66%
(19 of 29) of the E. faecalis strains could be assigned to one of
the four serogroups. Two additional strains were grouped into
two serogroups (types 2 and 5; Table 4).
Genetic diversity of capsular polysaccharides. The assign-
ment of a given strain to a serogroup was correlated with the
genetic organization of the cps locus, shown by Hancock and
Gilmore (10) to be involved in the biosynthesis of capsular
polysaccharides. Representative strains of the four serogroups
were chosen, and PCR was used to test for the presence of the
11 cps genes (Table 5). Two different patterns could be shown:
E. faecalis strains of the strain 12030- and 12107-related groups
FIG. 3. Phagocytic inhibition assay of the four prototype groups of sera against the four prototype E. faecalis (EFS) strains. Each prototype
serum was tested against its homologous prototype E. faecalis strain by absorption with the respective homologous strain and with the three
heterologous strains. The percent inhibition values reflect the ratio of the amount of absorbed sera to the amount of unabsorbed sera. The killing
activities of the four types of sera were most effectively inhibited by absorption with the homologous strain (100% for E. faecalis 12030, 84% for E. faecalis
12107, 66% for E. faecalis type 5). Type 2-specific sera could not be absorbed to the same degree (absorption, 34%). Inhibition of killing activity
by heterologous strains was greatly reduced for all four prototype sera, with cross-reactivity between strains E. faecalis 12030 and E. faecalis 12107.
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consistently possessed only the first two genes of the cps locus
(i.e., cpsA and cpsB), while all strains of the type 2- and type
5-related groups had the cpsA to cpsE and the cpsG to cpsK
genes. The cpsF gene was consistently missing from the type
5-related strains and was variably present in the type 2-related
strains. No specific pattern could be observed for the nontype-
able strains. The results of the PCR were verified by Southern
blot hybridization analysis. Hybridization analysis of DNA
digested with ClaI, using the 14.8-kb cpsA to cpsK fragment
amplified from strain V583 as a probe, demonstrated various
degrees of conservation among the isolates examined. Strains
belonging to the E. faecalis 12030 and E. faecalis 12107 groups
all showed an RFLP class I pattern, with only a single hybrid-
ization band, the size of which corresponds to those of the cpsA
and cpsB genes, as well as a conserved region downstream of
cpsK (Fig. 4). E. faecalis type 5 strains yielded an RFLP class II
pattern and were more closely related to class III strains than to
the other classes of strains, with the class II and class III strains
appearing to differ by only a single ClaI restriction fragment.
The difference between RFLP class II and III strains is likely
attributable to the absence of the cpsF gene in the class II
strains. The 5.7-kb ClaI fragment, which spans the 3 end of
cpsE through the 5 end of cpsJ and which is present in class III
strains, is absent from class II strains. However, a conserved
4.7-kb ClaI fragment from class II strains hybridizes to the
probe (Fig. 4). An apparent ClaI polymorphism was observed
for class II strains. With the exception of the 2.4-kb ClaI
fragment, E. faecalis type 5 and type 6 strains have ClaI re-
striction patterns identical to those of E. faecalis types 12, 14,
and 18. In place of the 2.4-kb fragment, E. faecalis type 5 has
a slightly smaller ClaI fragment of approximately 1.8 kb,
whereas E. faecalis type 6 has a much larger ClaI fragment of
6.0 kb (Fig. 4). E. faecalis class III strains previously identified
as being reactive with type 2-specific serum (10), namely,
E. faecalis FA2-2, E. faecalis V583, and E. faecalis MMH 594,
showed identical hybridization patterns with the E. faecalis
type 2 prototype strain (Fig. 4).
TABLE 4. Proposal for a serotyping system for E. faecalis based on
capsular polysaccharides and their relationship with the cps locusa
Proposed
serogroup
E. faecalis
strain
Homology by: RFLP
pattern of
CPS locusCPS-ELISA
Opsonophago-
cytic assay
CPS-A 12030 12030 12030 I
Type 3 12030 I
Type 7 12030 12030 and 12107 I
CPS-B 12107 12107 12107 I
OG1-RF 12107 12107 I
Type 1 12107 I
Type 10 12107 I
Type 16 12107 I
Type 20 12107 I
CPS-C Type 2 Type 2 Type 2 III
V583 Type 2 Type 2 and type 5 III
FA2-2 Type 2 Type 2 and type 5 III
R19.001 Type 2 Type 2 NDb
Type 12 Type 2 Type 2 and type 5 II
Type 14 Type 2 Type 2 and type 5 II
Type 21 Type 2 II
CPS-D Type 5 Type 5 Type 2 and type 5 II
68114 Type 5 Type 2 and type 5 ND
Type 18 Type 5 Type 2 and type 5 II
CPS-C and
CPS-D
MMH 594 Type 2 and
type 5
III
Type 6 Type 5 Type 2 II
NTc Type 4 I
Type 8 III
Type 9 I
Type 11 III
Type 13 I
Type 15 I
Type 17 I
Type 19 I
a E. faecalis strains were assigned to one of the four capsular polysaccharide
serotypes (CPS-A to CPS-D) if the definition criteria for one of the two diag-
nostic assays were met or if one assay eliminated cross-reactivity between two
serotypes in the second assay. Boldface indicates the prototype strain.
b ND, not determined.
c NT, nontypeable.
TABLE 5. PCR analysis of the cps locus in a representative collection of E. faecalis strains
Proposed
serogroup
E. faecalis
strain
Result for gene:
cpsA cpsB cpsC cpsD cpsE cpsF cpsG cpsH cpsI cpsJ cpsK
CPS-A 12030           
Type 7           
CPS-B 12107           
Type 1           
OG1-RF           
CPS-C Type 2           
FA2-2           
Type 12           
R19.001           
CPS-D Type 5           
Type 18           
CPS-C and CPS-D MMH 594           
NTa Type 9           
a NT, nontypeable.
b , present; , absent.
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Capsule-specific reactivity of antisera. To confirm the hy-
pothesis that the typing sera reacted with capsular antigens en-
coded by the cps locus, a CPS-ELISA (data not shown) and an
opsonophagocytic assay were performed with the acapsular
mutant HG101 and its wild-type (WT) capsular strain, E. fae-
calis FA2-2 (Fig. 5). E. faecalis FA2-2 reacts specifically with
type 2-specific serum (10). NRS was used as a negative control.
The WT strain was resistant to killing by NRS, whereas the
capsule-negative mutant was highly susceptible to killing by
NRS. Type 2-specific serum killed both strains efficiently. Ab-
sorption of the serum with the WT strain abolished the killing
activity against the WT strain but not the mutant, and absorp-
tion of the serum with the mutant had little or no effect on the
killing activity of the type 2-specific serum. These data support
the hypothesis that the activity of the type 2-specific serum is
directed against the capsule produced at least in part by en-
zymes encoded by the cps locus.
DISCUSSION
An enterococcal surface antigen that is the target of opsonic
antibodies has previously been isolated from E. faecalis 12030
and characterized (16). Compositional and structural analyses
of this antigen revealed a teichoic acid composed of a repeat-
ing unit of -D-glucopyranosyl-(1-2)--D-glucopyranose (koji-
bose) attached to a glycerol diphosphate (16, 27). Passive and
active immunotherapies reduced the bacterial counts in a
mouse model of bacteremia when the animals were challenged
with the homologous strain. This serum also protected mice
when they were challenged with a vancomycin-resistant E. fae-
cium strain (15). However, it is not known how many structur-
ally and immunologically different capsular polysaccharides
that may be used as vaccine candidates exist in enterococci.
Earlier studies by Sharpe (23), Sharpe and Shattok (24), and
Maekawa et al. (18, 19) attempted to establish systems for the
serotyping of enterococci. The latter scheme was based on 6 of
Sharpe’s original prototype strains, 2 strains from the Centers
for Disease Control and Prevention, and 13 clinical isolates
from Japan (19). In order to relate our present findings to
those of previous investigators, we included the strain collec-
tion of Maekawa et al. (19) in the present effort, since these
isolates represent E. faecalis strains with a high degree of
antigenic diversity (although the diversity is not necessarily
based solely on carbohydrate antigens). Maekawa’s collection
also included the strains from the study of Sharpe (23) and that
of Sharpe and Shattok (24).
A CPS-ELISA was developed on the basis of the preferen-
tial extraction of cell wall teichoic acids. In the assay, we used
sera that were absorbed with different heterologous strains
(Table 2). The four prototype strains used in this study were
chosen for the following reasons: the capsular polysaccharide
structure of E. faecalis 12030 has been elucidated (16, 27). The
opsonic killing activities of antibodies against the purified cap-
sular polysaccharide from this strain were tested against a
collection of clinical isolates, and it was found that 33% of the
strains were killed by this serum (16). One of these strains
(E. faecalis 12107) was not killed by this serum, and prelimi-
nary structural analysis of capsular polysaccharide material
from this strain indicated that its cell wall teichoic acid struc-
ture may be different from that of E. faecalis 12030 (unpub-
lished data).
In studies performed by Maekawa and Habadera (18), 30%
of urinary tract isolates were of the type 2 serotype. Studies
performed contemporaneously by Hancock and Gilmore (10)
indicated that the cps locus in the 21 Maekawa prototype
strains showed three different patterns, with E. faecalis 12030
and E. faecalis 12107 being indistinguishable by this method.
However, two additional patterns were observed, and E. fae-
calis type 2 and E. faecalis type 5 were arbitrarily chosen as
representatives of the remaining two RFLP patterns, respec-
tively.
The four types of sera used in this study were all directed
against capsular polysaccharides and reacted specifically with
the respective prototype strain, independently of the method
used to raise the sera. Immunoelectron microscopy of the four
prototype strains reacting with the respective sera clearly
showed that the capsule is the target of the antibodies (Fig. 1).
However, E. faecalis type 2 and E. faecalis type 5 showed cer-
FIG. 4. Southern blot analysis of capsular polysaccharide determi-
nants from various E. faecalis strains. DNA was restricted with ClaI
and probed with the radiolabeled fragment of the cpsA to cpsK genes
from E. faecalis strain V583. Lanes 1 to 5, strains with RFLP pattern
I; lanes 6 to 10, strains with RFLP pattern II; lanes 11 to 15, strains
with RFLP pattern III. Lane 1, E. faecalis 12107; lane 2, E. faecalis
12030; lane 3, E. faecalis type 4; lane 4, E. faecalis type 1; lane 5, E.
faecalis type 7; lane 6, E. faecalis type 6; lane 7, E. faecalis type 5; lane
8, E. faecalis type 18; lane 9, E. faecalis type 14; lane 10, E. faecalis type
12; lane 11, E. faecalis type 8, lane 12, E. faecalis type 2; lane 13, E.
faecalis MMH 594; lane 14, E. faecalis V583; lane 15, E. faecalis FA2-2.
The sizes (in base pairs) of the E. faecalis V583 sequence fragments
hybridizing to the probe are shown at the left. The ClaI restriction map
for the E. faecalis V583 capsular polysaccharide determinant is shown
below. The molecular sizes (in base pairs) of the regions spanned by
the ClaI sites in E. faecalis V583 are listed below the map.
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tain degrees of cross-reactivity. Heat inactivation and protein-
ase K treatment of whole bacterial cells elicited antibodies
directed against capsular structures, a finding which is con-
firmed by the opsonophagocytic assay with WT E. faecalis
strain FA2-2 and its capsule-negative mutant, HG101. The WT
strain was killed only by the type 2-specific serum, indicating that
the serum contained opsonic antibodies directed against the cap-
sule. In contrast, the capsule-negative mutant was already sen-
sitive to killing by preexisting natural antibodies in NRS, which
were not necessarily directed against the capsule. A similar
phenomenon has been observed previously (2, 3, 15, 16).
In order to increase the specificity of the reactivities of the
four types of sera against capsular polysaccharides, we used
TCA extraction to isolate crude polysaccharide antigens from
the bacterial cells in the CPS-ELISA. We found that the pro-
tein levels in TCA extracts were below the detection limit of
the modified Bradford assay used. Treatment of TCA extracts
with sodium periodate reduced the carbohydrate content to
18% of that of pure TCA extracts and reduced the reactivity
with the type-specific serum to 8% (data not shown), indicating
that the majority of the antibody binding activity was to a
carbohydrate antigen. In contrast, treatment of the TCA ex-
tract with proteinase K had no effect on the reactivities of the
antisera (98% of that of pure TCA extracts). From these data
we conclude that the TCA extracts primarily consisted of car-
bohydrate antigens, with the majority presumably being cap-
sular polysaccharide antigens. This assumption was further
supported by the observation that type 2-specific serum re-
vealed a strong reactivity with E. faecalis FA2-2 (OD405, 1.860)
but a strongly reduced reactivity with capsule-negative mutant
HG101 (OD405, 0.526).
Using the criteria mentioned above to assign an isolate to
one of the four serogroups, we were unequivocally able to
group 55% of the strains tested. However, one of the serum
types (i.e., the type 2-specific serum) showed a high degree of
cross-reactivity with a different prototype strain (i.e., E. faecalis
type 5). This may be explained by chemical and/or structural
similarities of the different polysaccharides, a situation not
uncommon for polysaccharide antigens from other bacteria (5,
25). Alternatively, a given strain may be able to produce two
different variant forms of carbohydrate antigen, depending on
the conditions used.
To correlate the data obtained by CPS-ELISA with the bi-
ological response (i.e., opsonic killing) relevant to the intended
use of the antigens as the basis of a vaccine, we compared the
results obtained by CPS-ELISA with those obtained by an
opsonophagocytic assay. While the majority of strains reacted
identically in the opsonophagocytic assay, we also observed
some differences. The high degree of cross-reactivity between
E. faecalis type 2 and E. faecalis type 5 in the opsonophagocytic
assay points toward the possibility that these two antigens have
close structural similarity. Taking into account this cross-reac-
tivity, as well as the number of strains that were not typeable by
both methods, the agreement between the two assays was 72%.
FIG. 5. Comparison of E. faecalis strains FA2-2 and HG101 in the opsonophagocytic assay with NRS and the type 2-specific sera. Negative
killing reflects growth during the 90-min incubation period of the assay.
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Four strains could be grouped only by the opsonophagocytic
assay, perhaps because the amount of specific polysaccharide
on the surface of the bacterial cell was too small to be detected
by the CPS-ELISA. This amount of antigen may still provide
enough antigenic epitopes for opsonization, leading to killing
in the opsonophagocytic assay. One of the two strains typeable
only by CPS-ELISA (Maekawa strain type 20) was highly re-
sistant to killing by any of the sera, and factors other than
capsule production that contribute to serum resistance may be
responsible for this effect. The other strain, E. faecalis type 1,
was highly sensitive to killing by all four types of sera, including
NRS (data not shown), suggesting that this strain was unable to
resist non-antibody-mediated opsonic killing, even though it
has a capsule.
To date there is no proven link between the structure of
capsular polysaccharide and a genetic locus responsible for the
biosynthesis of the capsular polysaccharide. E. faecalis 12030 is
the only strain for which structural analysis of the capsular
polysaccharide has been performed (16, 27). The cps locus is
known to be involved in the biosynthesis of capsular polysac-
charides (10), but so far only a compositional analysis of the
respective antigen exists. The homology of one of the enzymes
within this gene locus with a glycerophosphotransferase in-
volved in the synthesis of teichoic acids in Bacillus subtilis and
the presence of quantitative amounts of phosphate indicate
that the locus described by Hancock and Gilmore (10) may be
responsible for the production of the capsular polysaccharide
described by Huebner and colleagues (16, 27). Three different
organizations of the gene locus have been observed: E. faecalis
12030 and E. faecalis 12107 showed an RFLP class I pattern,
with the presence of only two open reading frames, i.e., cpsA
and cpsB. Both of these genes may be essential in E. faecalis,
and they are present in all strains tested so far, independent of
their serotype.
Hancock and Gilmore (11) and Xu et al. (28–30) have de-
scribed a different locus involved in the synthesis of an integral
enterococcal cell wall polysaccharide. While Huebner and col-
leagues (16, 27) were able to isolate and initially characterize a
similar tetraheteroglycan material from the cell wall of our
prototype strain, E. faecalis 12030, this antigen is distinct from
the teichoic acid-like capsular polysaccharides, and the prep-
aration of this tetraheteroglycan shows no immunoreactivity
with serum raised against the capsular polysaccharides exam-
ined here (data not shown).
E. faecalis type 2- and E. faecalis type 5-related strains, which
we refer to as the CPS-C and the CPS-D serogroups, respec-
tively, possessed at least 10 of the 11 genes of the cps locus.
While strains of the CPS-D serogroup did not contain the cpsF
gene, its presence was variable in CPS-C strains. At present, it
is unclear why RFLP class II strains represent both CPS-C and
CPS-D strains. Some class II strains (i.e., E. faecalis types 5 and
18) react with type 5-specific serum in the CPS-ELISA, where-
as others (i.e., E. faecalis types 12 and 14) react with type
2-specific serum. E. faecalis strain MMH 594, which was pre-
viously shown to react with type 2-specific serum (10), pro-
duced a hybridization pattern identical to that of RFLP class
III strains; but it is now known that it cross-reacts with type
5-specific serum, which suggests that it may modulate expres-
sion of its cps genes, possibly leading to antigenic variation
through the expression of multiple serotypes. Interestingly, E.
faecalis type 8 produced the same hybridization profile as E.
faecalis type 2 (Fig. 4) but was nontypeable with type 2-specific
serum. It remains unclear how E. faecalis types 2, 8, and 11
(data not shown) can yield identical restriction patterns for the
cps determinant yet still be serologically distinct. It is possible
that E. faecalis types 8 and 11 have lost the ability to produce
the capsular serotype, thus exposing alternative typing anti-
gens. Alterations in promoter sequences or the presence of
regulatory elements could modulate the extent to which the
polysaccharide is expressed. Alternatively, the product(s) of
polysaccharide biosynthetic genes not found in the cps deter-
minant could alter the capsular structure through the place-
ment of additional carbohydrate residues on the capsular poly-
saccharide.
The presence of the genes in the cps locus does not com-
pletely explain the serologic specificity observed. Structural
analysis of defined knockout mutants may be able to determine
whether the difference between CPS-C and CPS-D can be
explained by the expression of the cpsF gene. The additional
genes that are probably necessary for the production of the
CPS-A and CPS-B polysaccharides need to be identified and
sequenced.
It appears that E. faecalis capsular polysaccharides have
evolved from two distinct families. The first family comprises
lineages containing all (RFLP class III) or most (RFLP class
II) of the cpsC to cpsK determinant, whereas the second family
consists of a third lineage that lacks this determinant. The
importance of the capsular polysaccharide to the biology of the
organism would suggest that at some time in the distant past
the second family acquired the ability to make a capsule, in-
dependent of the cps determinant. A closer examination of the
Southern blot analysis (Fig. 4) reveals additional faint bands
for DNA from strains of the second family, suggesting that the
evolution of capsular polysaccharide diversity in this family
may have paralleled that in the first family to allow some cross
hybridization with related genes located elsewhere on the
chromosome. This observation is consistent with the evolution
of capsular polysaccharide determinants in other organisms
(22). In Staphylococcus aureus, the capsular polysaccharides of
serotypes 5 and 8 are similar and their biosynthetic genes occur
at the same point on the S. aureus genomic map, whereas the
determinant for type 1 capsule biosynthesis occurs elsewhere
on the chromosome. The limited homology between these
genetic pathways is detectable only by hybridization under
low-stringency conditions, even though the structures of the
type 1, 5, and 8 capsular polysaccharides are similar (22).
From the present data we conclude that a limited number of
enterococcal serogroups exist. The four serogroups described
here represent a major portion (about 60%) of clinically rele-
vant E. faecalis isolates. The methods described here can be
used to identify strains with serologically different polysaccha-
rides. Ongoing studies aimed at identifying additional sero-
groups have so far not given an indication of any serologically
diverse polysaccharide capsules (data not shown). The pres-
ence of strains that do not react with our antisera may be due
to the absence of a polysaccharide capsule in these strains.
In contrast to the studies of Sharpe and Shattok (24), we
investigated the serologic diversity of enterococcal polysaccha-
rides not for epidemiologic analysis but for better evaluation
of the feasibility of immunotherapy regimens based on capsu-
2556 HUFNAGEL ET AL. J. CLIN. MICROBIOL.
lar polysaccharide antigens. Serotyping of bacteria has been
widely used as a tool in bacterial epidemiology. Powerful new
molecular typing methods have replaced this technique. Meth-
ods such as pulsed-field gel electrophoresis (26) have better
discriminatory power, and randomly amplified polymorphic
DNA analysis (4) and multilocus sequence typing (14) are also
able to show phylogenetic and evolutionary relationships be-
tween strains. Studies are under way to elucidate the possible
relationships between serogroups and the evolutionary lin-
eages of enterococcal strains of different geographical origins.
Compositional and structural analyses of the polysaccha-
rides are under way to confirm the serogroups described here.
These data will facilitate the comprehensive establishment of a
system for the serotyping of enterococci and will help to de-
termine the relevant serotypes to be included in a broadly
active enterococcal polysaccharide vaccine. The limited num-
ber of serotypes found so far suggests that the development of
an enterococcal vaccine will be feasible.
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